Share Buyback Plan Authorized by IQVIA (NYSE:IQV) Board

Key Points

• IQVIA's board authorized a share repurchase program of $2.0 billion, permitting buybacks of up to 6.8% of outstanding shares.
• The company beat Q1 expectations with $2.90 EPS (vs. $2.83 est.) and $4.15 billion in revenue, and set FY2026 EPS guidance of 12.65–12.95.
• Shares rose about 1.4% to $178.95 on the news, and analysts maintain a consensus "Buy" rating with an average target of $225.69.

IQVIA (NYSE:IQV - Get Free Report) announced that its board has approved a share repurchase program on Thursday, May 7th, RTT News reports. The company plans to repurchase $2.00 billion in outstanding shares. This repurchase authorization allows the medical research company to purchase up to 6.8% of its stock through open market purchases. Stock repurchase programs are often a sign that the company's board of directors believes its shares are undervalued.

IQVIA Stock Up 1.4%

Shares of IQV traded up $2.48 during mid-day trading on Thursday, hitting $178.95. 1,803,056 shares of the company's stock were exchanged, compared to its average volume of 1,754,590. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20. IQVIA has a twelve month low of $134.65 and a twelve month high of $247.04. The firm has a fifty day moving average of $170.14 and a two-hundred day moving average of $200.95. The stock has a market cap of $29.87 billion, a price-to-earnings ratio of 22.17, a P/E/G ratio of 1.75 and a beta of 1.18.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings data on Tuesday, May 5th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.83 by $0.07. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The firm had revenue of $4.15 billion during the quarter, compared to analysts' expectations of $4.10 billion. During the same period in the prior year, the company posted $2.70 earnings per share. IQVIA's revenue for the quarter was up 8.4% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, sell-side analysts forecast that IQVIA will post 11.5 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on IQV shares. Stifel Nicolaus cut their price objective on IQVIA from $273.00 to $220.00 and set a "buy" rating for the company in a research report on Friday, February 6th. Truist Financial cut their price objective on IQVIA from $290.00 to $245.00 and set a "buy" rating on the stock in a report on Thursday, February 19th. Barclays raised shares of IQVIA from an "equal weight" rating to an "overweight" rating and set a $210.00 target price on the stock in a research report on Friday, March 6th. Evercore reaffirmed an "outperform" rating and issued a $185.00 price objective on shares of IQVIA in a research note on Wednesday, April 8th. Finally, Weiss Ratings lowered IQVIA from a "hold (c)" rating to a "hold (c-)" rating in a report on Monday. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, IQVIA has a consensus rating of "Buy" and an average target price of $225.69.

IQVIA Company Profile

IQVIA NYSE: IQV is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA's principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.